Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation

NCT03182244 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT03182244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03182244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation
Lead sponsor
Astellas Pharma Inc
Phase
Phase 3
Overall status
Completed
Start date
October 25, 2017
Completion date
July 29, 2026
Enrollment
276 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

aml with flt3 mutation